TLSI (TLSI) Securities Fraud Investigation - Levi & Korsinsky

On March 5, 2026, TriSalus Life Sciences Inc. confirmed its revenue guidance for the year to be between $60 million and $62 million. However, following a shortfall in Q1 estimates, the company revised its forecast to $54 million to $57 million. On May 22, 2026, in New York, TriSalus Life Sciences Inc. (TLSI) shareholders experienced a decrease in the value of their shares after the revenue guidance adjustment.